Since ERα mediates the growth and development of several cancers, it has been identified as a major therapeutic target and, therefore, vast arrays of ERα selective ligands have been developed and studied for their potential in controlling the growth of tumor cells by competitively blocking the action of the endogenous ligand estradiol (E2) on ERα8, 10. The gene discussed is ESR1; the disease is neoplasm.